- ISIN
- US74907L1026
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 29, 2016
Highlights
- Market Cap
- $12.48M
- Enterprise Value
- $9.36M
- EPS (TTM)
- -$13.39
- Gross Profit (TTM)
- -$24.93K
- EBITDA (TTM)
- -$17.28M
- Year Range
- $4.10 - $41.80
- ROA (TTM)
- -108.27%
- ROE (TTM)
- -193.66%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
QNRX Performance Chart
Quoin Pharmaceuticals Ltd DRC (QNRX) is down 69.4% since the beginning of the year. At $4 per share, QNRX is trading 89.4% below its 52-week high of $42. Investors who bought $1,000 worth of QNRX shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Returns By Period
Quoin Pharmaceuticals Ltd DRC (QNRX) has returned -69.44% so far this year and -49.31% over the past 12 months.
Quoin Pharmaceuticals Ltd DRC
- 1D
- -5.16%
- 1M
- -7.55%
- YTD
- -69.44%
- 6M
- -67.93%
- 1Y
- -49.31%
- 3Y*
- -73.86%
- 5Y*
- -85.89%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
QNRX Monthly Returns History
Based on dividend-adjusted daily data since Jul 29, 2016, QNRX's average daily return is -0.09%, while the average monthly return is -5.46%.
Historically, 37% of months were positive and 63% were negative. The best month was Feb 2017 with a return of +112.8%, while the worst month was Nov 2021 at -67.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 9 months.
On a daily basis, QNRX closed higher 42% of trading days. The best single day was Aug 3, 2022 with a return of +360.5%, while the worst single day was Aug 5, 2022 at -62.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -50.00% | 16.01% | -21.15% | -1.82% | -21.91% | -12.85% | -69.44% | ||||||
| 2025 | -48.82% | -6.70% | -27.94% | -13.63% | 26.02% | 8.21% | -27.41% | 10.08% | -2.51% | 57.16% | 92.48% | -33.66% | -36.64% |
| 2024 | -27.22% | -22.97% | -65.46% | -25.48% | 9.78% | -25.36% | 3.52% | 4.28% | -21.26% | 51.54% | -19.69% | 8.45% | -86.73% |
| 2023 | 17.61% | -65.89% | -16.50% | 5.13% | -14.90% | 17.58% | 31.08% | -26.94% | -27.83% | -1.93% | 22.19% | -1.37% | -71.21% |
| 2022 | -23.63% | -20.14% | 19.82% | -39.76% | -20.74% | -29.09% | -20.79% | -26.66% | -31.80% | -17.04% | -9.73% | -14.97% | -93.76% |
| 2021 | 33.33% | 15.97% | -5.99% | -19.75% | 24.21% | 19.81% | 13.87% | 24.12% | -12.92% | -36.94% | -67.44% | -51.98% | -78.94% |
Benchmark Metrics
Quoin Pharmaceuticals Ltd DRC has an annualized alpha of -31.66%, beta of 1.06, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since July 29, 2016.
- This stock participated in 241.95% of S&P 500 Index downside but only -90.76% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -31.66%
- Beta
- 1.06
- R²
- 0.01
- Upside Capture
- -90.76%
- Downside Capture
- 241.95%
Return for Risk
Risk / Return Rank
QNRX ranks 34 for risk / return — below 34% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Quoin Pharmaceuticals Ltd DRC (QNRX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| QNRX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.29 | ||
| Sortino ratioReturn per unit of downside risk | -2.04 | ||
| Omega ratioGain probability vs. loss probability | 1.09 | 1.37 | -0.28 |
| Calmar ratioReturn relative to maximum drawdown | -0.61 | 2.78 | -3.39 |
| Martin ratioReturn relative to average drawdown | -0.98 | 12.44 | -13.41 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Quoin Pharmaceuticals Ltd DRC. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Quoin Pharmaceuticals Ltd DRC was 100.00%, occurring on Jun 12, 2026. The portfolio has not yet recovered.
The current Quoin Pharmaceuticals Ltd DRC drawdown is 100.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -100.00%Jun 2026 | 9y 2mo | — | 9y 2moMar 2017 - now |
2016 bear market2016 | -50.74%Dec 2016 | 4mo 25d | 22d | 5mo 17dJul 2016 - Jan 2017 |
2017 bear market2017 | -49.31%Jan 2017 | 18d | 14d | 1mo 2dJan 2017 - Feb 2017 |
2017 correction2017 | -13.28%Mar 2017 | 19d | 5d | 24dMar 2017 - Mar 2017 |
2017 pullback2017 | -9.97%Feb 2017 | 0s | 7d | 7dFeb 2017 - Mar 2017 |
Drawdown Indicators
| QNRX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -81.17% | -9.10% | -72.07% |
Max Drawdown (3Y)Largest decline over 3 years | -98.68% | -18.90% | -79.78% |
Max Drawdown (5Y)Largest decline over 5 years | -100.00% | -25.43% | -74.57% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -100.00% | -1.80% | -98.20% |
Average DrawdownAverage peak-to-trough decline | -81.53% | -10.71% | -70.82% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 50.56% | 2.03% | +48.53% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Quoin Pharmaceuticals Ltd DRC over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Quoin Pharmaceuticals Ltd DRC is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for QNRX in comparison with other companies in the Biotechnology industry. Currently, QNRX has a P/B value of 1.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with QNRX
Add Quoin Pharmaceuticals Ltd DRC to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with QNRX